Abstract
Binuclear dithiocarbamate complexes of Ru(III) are promising candidates in the search for outstanding metal-based anticancer agents. While different dithiocarbamates have shown ligand-dependent cytotoxicity in homoleptic binuclear Ru(III) complexes, the properties of heteroleptic analogues with different dithiocarbamate (DTC) ligands have yet to be explored. We herein propose the introduction of heteroleptic ligands as tunable features for the development of improved ruthenium-based antiproliferative agents and report a synthetic strategy for their synthesis as well as the evaluation of the cytotoxic activity of a selection of binuclear heteroleptic Ru(III) compounds towards MDA-MB-231 and PC3 cells.
| Original language | English |
|---|---|
| Article number | 37 |
| Journal | Inorganics |
| Volume | 10 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 17 Mar 2022 |
Bibliographical note
Funding Information:This research was funded by A.R.TE.M.O. ONLUS Association (via Campolongo 4E Padova, Italy, N? Registro 3524, C.F. 93046520255. A PhD fellowship was granted to N.P. by T.R.N. IMBALLAGGI?logistics services, 29 February 2016, Prot. 539, Tit. III, Cl.13, Fasc. 3. A.E.G. is grateful to the Engineering and Physical Sciences Research Council for a PhD studentship. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.